Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Core Viewpoint - Citius Oncology, Inc. has entered into a securities purchase agreement to raise approximately $9.0 million through a registered direct offering and a concurrent private placement, involving the sale of 5,142,858 shares of common stock and unregistered warrants [1][2]. Group 1: Offering Details - The effective offering price for each share of common stock and accompanying warrant is set at $1.75, with warrants having an exercise price of $1.84 per share, exercisable six months from issuance and expiring five and a half years later [1][2]. - The offering is expected to close around September 10, 2025, pending customary closing conditions [2]. Group 2: Company Background - Citius Oncology focuses on developing and commercializing novel targeted oncology therapies, with its primary asset, LYMPHIR, approved by the FDA for treating adults with relapsed or refractory CTCL [5]. - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, supported by robust intellectual property protections [5]. - Citius Pharmaceuticals, the parent company, is dedicated to first-in-class critical care products, with a late-stage pipeline that includes Mino-Lok® and CITI-002 (Halo-Lido) [6].